Genghis Lloyd-Harris, Partner, Abingworth
Andrew Kay, CEO, Algeta ASA
Nicholas Adams, Vice President, Business Development, Antisoma Research Limited
Lionel Carnot, Partner, Bay City Ventures
Lubor Gaal, Executive Director, Head of Europe, Strategic Transaction Group, Bristol-Myers Squibb
Stephanie Léouzon, Managing Director, European Healthcare, Credit Suisse
Dimitri F. Dimitriou, Chief Executive Officer, DyoDelta Biosciences
Prof Malcolm Young, Chief Executive Officer, e-Therapeutics
Raphael Wisniewski, Partner, Edmond de Rothschild Investment Partners
Andrew Wood, Executive Director, Eli Lilly & Company
Kees Been, CEO, EnVivo Pharmaceuticals
Nigel Sheail, VP, Head of Roche Corporate Business Development, F.Hoffmann-La Roche Ltd
Dr Christina Takke, Principal, Forbion Capital Partners
Arthur Franken, Partner, Gilde Investment Management B.V.
Jacob Gunterberg, Partner, HealthCap
Stan Yakatan, Chairman, Katan Associates
Margaret Beer PhD, Senior Director and Head Licensing and External Research, Europe, Merck & Co
Dr Rüdiger Weseloh, Senior Director Head Negotiation, Early Stage Licensing, Merck Serono SA
Roel Bulthuis, Head of Merck Serono Ventures, Merck Serono Ventures
Ansbert Gadicke, Managing Director, MPM Capital
Esteban Pombo Villar, Head of Strategic Alliance Management EU, Novartis Pharma AG
Adrian Dawkes, Managing Consultant, PharmaVentures Ltd
Nigel Sheail, Vice President, Global Head Licensing, Pharma Partnering, Roche Pharmaceuticals
Simon Meier, Investment Director, Roche Venture Fund
Barbara Heller, CFO, Santhera Pharmaceuticals
David Colpman, Senior Vice President, Business Development, Shire Pharmaceuticals Group
Andrea Isler, Relationship Manager, Issuers & Investor Relations, SIX
Swiss Exchange AG
Philipe Lutz, CEO, Synosia Therapeutics
Karl Naegler, General Partner, Ventech
*to be confirmed